Navigation Links
Iomai Reports 'Going Concern' Qualification in 10-K
Date:3/28/2008

GAITHERSBURG, Md., March 28 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced, in compliance with NASDAQ marketplace rules, that the independent audit report included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2008 for the fiscal year ended December 31, 2007 contained a "going concern" qualification. This disclosure is required under NASDAQ marketplace rules and does not represent any change to the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and filed on March 27, 2008 with the SEC.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.


'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
2. Iomai CEO to Speak at Cowen and Company Health Care Conference on Monday, March 17
3. Iomai Study Shows Self-Applied Travelers Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch
4. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
5. Hospital for Special Surgery Reports Scores on HCAHPS Survey
6. PreMD Reports Fiscal 2007 Results
7. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
8. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
9. Spheris Reports Fourth Quarter and Year-End 2007 Results
10. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
11. QMed, Inc. Reports Year-End and Fourth Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... 2016 , ... Shark Finds and Kevin Harrington, along with the ... campaign with Belly Bands. , Having a dog is great—except when it wets every ... find nothing works, get Belly Bands, the easiest way to stop dogs from ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Love is in ... in a variety of colors, assortments and packaging. This staple for Valentine’s Day is ... Kullen location. , For Valentine’s Day, not only are long-stem roses available, but ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... stage for new clinical and scientific initiatives have all marked the last 12 ... appointed President and CEO of the nation’s oldest cancer center, Candace S. Johnson, ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... of micro-needling services in their Napa Valley office. The technique utilizes the body’s ... Associates, Dr. Canales and Dr. Furnas, are part of only a select few ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active ... Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division ... completed his first three-year term as chief and began a second three-year term in ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Wegener Polyangiitis ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline Review, ... Polyangiitis,s therapeutic pipeline. This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... SILVER SPRING, Md. , Feb. 4, 2016 ... Robert Califf , the FDA,s Deputy Commissioner for Medical Products ... far-reaching action plan to reassess the agency,s approach to opioid ... the epidemic, while still providing patients in pain access to ... The FDA will: , Re-examine the risk-benefit ...
Breaking Medicine Technology: